Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

NCT01627613 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lung Injury

Interventions

DRUG: AP301
DRUG: Saline solution

Sponsor

Apeptico Forschung und Entwicklung GmbH